WO2005042692A3 - A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors - Google Patents

A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors Download PDF

Info

Publication number
WO2005042692A3
WO2005042692A3 PCT/CA2004/002028 CA2004002028W WO2005042692A3 WO 2005042692 A3 WO2005042692 A3 WO 2005042692A3 CA 2004002028 W CA2004002028 W CA 2004002028W WO 2005042692 A3 WO2005042692 A3 WO 2005042692A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
expression
genes
cholesterol
production
Prior art date
Application number
PCT/CA2004/002028
Other languages
French (fr)
Other versions
WO2005042692A2 (en
Inventor
Kristina Sachs-Barrable
Tatjana Lukic
David John Stewart
Kishor M Wasan
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of WO2005042692A2 publication Critical patent/WO2005042692A2/en
Publication of WO2005042692A3 publication Critical patent/WO2005042692A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

The present invention provides, in one aspect, a method of inhibiting the expression of a gene which mediates cellular cholesterol influx in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, it provides a method of inhibiting the production of a protein expressed by a gene which mediates cellular cholesterol influx in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor.
PCT/CA2004/002028 2003-10-31 2004-11-01 A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors WO2005042692A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69794903A 2003-10-31 2003-10-31
US10/697,949 2003-10-31

Publications (2)

Publication Number Publication Date
WO2005042692A2 WO2005042692A2 (en) 2005-05-12
WO2005042692A3 true WO2005042692A3 (en) 2005-09-09

Family

ID=34550501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/002028 WO2005042692A2 (en) 2003-10-31 2004-11-01 A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors

Country Status (1)

Country Link
WO (1) WO2005042692A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN101243072A (en) 2005-06-20 2008-08-13 先灵公司 Piperidine derivatives useful as histamine H3 antagonists
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
RU2009108280A (en) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN114716491A (en) * 2021-11-25 2022-07-08 广西民族大学 Three compounds derived from Tougo lignin, and preparation method and application thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0665238A1 (en) * 1994-01-28 1995-08-02 Senju Pharmaceutical Co., Ltd. Corticoid derivatives and pharmaceutical and cosmetic compositions
WO1998001759A1 (en) * 1996-07-03 1998-01-15 Forbes Medi-Tech Inc. A method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
US5767115A (en) * 1993-09-21 1998-06-16 Schering-Plough Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5804576A (en) * 1983-08-02 1998-09-08 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17-ones and 5-androstan-17-ones
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO2000045648A1 (en) * 1999-02-03 2000-08-10 Forbes Medi-Tech Inc. Method of preparing microparticles of phytosterols or phytostanols
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
US20030130296A1 (en) * 2001-08-13 2003-07-10 Ulrike Bauer FXR NR1H4 nuclear receptor binding compounds
WO2003059360A1 (en) * 2002-01-11 2003-07-24 Medical Isotopes, Inc. Novel cholesterol absorption lowering agents
WO2003104254A2 (en) * 2002-06-06 2003-12-18 Forbes Medi-Tech Inc. Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804576A (en) * 1983-08-02 1998-09-08 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17-ones and 5-androstan-17-ones
US5767115A (en) * 1993-09-21 1998-06-16 Schering-Plough Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0665238A1 (en) * 1994-01-28 1995-08-02 Senju Pharmaceutical Co., Ltd. Corticoid derivatives and pharmaceutical and cosmetic compositions
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1998001759A1 (en) * 1996-07-03 1998-01-15 Forbes Medi-Tech Inc. A method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
WO2000045648A1 (en) * 1999-02-03 2000-08-10 Forbes Medi-Tech Inc. Method of preparing microparticles of phytosterols or phytostanols
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
US20030130296A1 (en) * 2001-08-13 2003-07-10 Ulrike Bauer FXR NR1H4 nuclear receptor binding compounds
WO2003059360A1 (en) * 2002-01-11 2003-07-24 Medical Isotopes, Inc. Novel cholesterol absorption lowering agents
WO2003104254A2 (en) * 2002-06-06 2003-12-18 Forbes Medi-Tech Inc. Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE JONG A. ET AL: "Metabolic effects of plant sterol and stanols(review).", J.NUTR.BIOCHEM., vol. 14, no. 7, July 2003 (2003-07-01), pages 362 - 369, XP002304146, DOI: doi:10.1016/S0955-2863(03)00002-0 *
KOSUBEK ET AL: "Liposomal Drug Delivery, A novel Approach: PLARosomes.", ACTA BIOCHIMICA POLONICA., vol. 47, no. 3, 2000, pages 639 - 649, XP002981870 *

Also Published As

Publication number Publication date
WO2005042692A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2006046148A3 (en) Rna constructs
WO2003093441A3 (en) A method of regulating gene expression
WO2005007196A3 (en) Lipid encapsulated interfering rna
WO2006031800A3 (en) Reverse transfection of cell arrays
WO2005099770A3 (en) Pancreatic islet microrna and methods for inhibiting same
WO2003102214A3 (en) Method for efficient rna interference in mammalian cells
WO2005030982A3 (en) Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
WO2004024757A3 (en) Modified pna molecules
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
IS7992A (en) Wild cell culture method
WO2007124493A3 (en) Methods and compositions for producing recombinant proteins using a gene for trna
WO2005085457A3 (en) Method and products for the selective degradation of proteins
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2005097205A3 (en) Dna virus microrna and methods for inhibiting same
WO2003062423A3 (en) Method for inhibiting the expression of a target gene resulting from a chromosome aberration
AU2003302134A1 (en) Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
WO2005000888A3 (en) NOVEL β-ACTIN AND RPS21 PROMOTERS AND USES THEREOF
WO2005108573A8 (en) METHOD TO INDUCE RNAi IN PROKARYOTIC ORGANISMS
WO2006047728A3 (en) Bmp gene and fusion protein
WO2005079367A3 (en) Schizochytrium fatty acid synthase (fas) and products and methods related thereto
WO2009140701A3 (en) Delivery into cells using ultra-short pulse lasers
WO2006017355A3 (en) Improved aprotinin variants
WO2007094818A3 (en) Novel hiv targets
WO2005067648A3 (en) Multiplex spatial profiling of gene expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase